| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
STORY UPDATE
LYONS, France—May 15, 2007—Animal model specialist genOway announced it successfully completed its initial public offering on Alternext to great interest, with demand outstripping supply 10-fold. The capital will provide resources for extending the company's R&D efforts through innovation and licensing.
 
 
WILMINGTON, Mass.—Charles River Laboratories announced recently the formation of a strategic alliance with Lyon, France-based genOway, a leader in genetically modified model organisms. The deal will see the two companies provide animal models of human disease to markets worldwide, combining the regional expertise of each partner. According to William Barbo, vice president of Research Model Services at Charles River, the North American company will promote genOway's solutions and further assist Charles River clients efficiently pursue their research goals.
 
Charles River is a market leader in model development, breeding services and model characterization, while genOway holds IP for a variety of research solutions including several knock-in and knock-out systems, as well as inducible-gene expression models.

"We are thrilled to begin this exciting new collaboration with Charles River promoting our wide array of proprietary solutions and services to the North American market," said Alexandre Fraichard, CEO of genOway. "Charles River, the acknowledged market leader in this segment, shares our commitment to unsurpassed customer service, and to offering clients what they truly want and need."

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A blue and orange double-helix representing DNA is undergoing transcription with a large orange shape representing RNA polymerase against a blue background

Harnessing CRISPR-Cas9: Knocking out genes in myeloid cells

Explore the applications of CRISPR-Cas9 technology in therapeutic development for Alzheimer’s disease.
A blue x-ray style image of a human body is shown with the liver illuminated in orange against a dark blue background.

Harnessing liver-on-a-chip models for drug safety

Discover how researchers leverage microphysiological systems in toxicology studies.  
A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

Enhancing bioanalytical studies with centralized data management

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue